Skip to main content
TipRanks
Go Ultimate75% OFF

AFYREN (ALAFY) AI Stock Analysis

1 Followers
FR:ALAFY

AFYREN

(Paris:ALAFY)

Select Model
Rating:45.3Neutral
Price Target:EUR 2.00â–¼(-10.31% Downside)
Action:reiterated
Date:09/17/26

The overall score is driven primarily by weak fundamentals: persistent revenue decline, negative margins, and worsening cash flows despite a solid, low-leverage balance sheet. Secondary pressure comes from mildly bearish technicals, with the price below major moving averages and modestly weak momentum. Valuation contributes modestly to the low score, as losses and the absence of a dividend limit valuation appeal based on the available metrics.

Positive Factors
Low financial leverageMaterial debt reduction and low leverage give AFYREN greater financial flexibility than its earnings profile alone would suggest. This can help preserve strategic options, reduce interest burden, and provide more capacity to fund operations while the company works toward sustainable profitability.
Negative Factors
Sustained revenue contractionRevenue contraction across consecutive years indicates that AFYREN has not yet established durable top-line momentum. Continued shrinkage can reduce operating scale, weaken absorption of fixed costs, and make it harder for the industrial platform to reach the volume needed for profitability.

AFYREN (ALAFY) vs. iShares MSCI France ETF (EWQ)

-10%0%10%20%30%40%FR:ALAFY0.00%EWQ+1.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 86.64M
Dividend Yield
―
Average Volume (3M)
10.67K
Price to Earnings (P/E)
-11.3
Beta (1Y)
0.01
Revenue Growth
-13.62%
EPS Growth
54.46%
Country
France
Employees
149
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

AFYREN Business Overview & Revenue Model

Company Description

AFYREN SAS provides biobased products to replace petroleum-based molecules in France. The company offers acetic, propionic, butyric and isobutyric, valeric and isovaleric, and caproic acids. Its products are used in the flavors and fragrances, lubric...

AFYREN Financial Statement Overview

Summary

Financial performance is weak overall: revenues are declining, margins are deeply negative, and net losses and operating cash burn are widening, partly offset by a deleveraged balance sheet and stable equity.

Income Statement

28Negative

Balance Sheet

72Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.33M2.27M2.86M3.38M3.46M3.04M
Gross Profit-10.71M-5.49M-174.00K645.00K1.06M1.47M
EBITDA-11.42M-6.81M-8.81M-8.59M-4.71M-2.78M
Net Income-5.01M-14.37M-9.75M-9.59M-9.20M-3.61M
Balance Sheet
Total Assets139.25M67.14M58.56M70.43M84.82M93.15M
Cash, Cash Equivalents and Short-Term Investments17.30M35.16M33.65M49.66M62.40M67.36M
Total Debt40.90M2.42M3.31M4.79M8.54M8.95M
Total Liabilities67.49M4.19M5.86M8.63M13.84M15.29M
Stockholders Equity71.76M62.10M52.70M61.80M70.98M77.86M
Cash Flow
Free Cash Flow-15.31M-5.29M-5.84M-5.60M-3.83M-3.06M
Operating Cash Flow-9.84M-5.09M-5.62M-5.04M-3.30M-2.71M
Investing Cash Flow-27.49M-15.25M-9.11M-3.08M-362.00K-436.00K
Financing Cash Flow27.17M21.96M-1.28M-4.66M-1.14M60.77M

AFYREN Technical Analysis

Technical Analysis SentimentNegative
Last Price2.23

Price Trends

50DMA2.39Negative
100DMA2.59Negative
200DMA2.63Negative

Market Momentum

MACD-0.05Negative
RSI43.47Neutral
STOCH58.06Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALAFY, the sentiment is Negative. The current price of 2.23 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.39, and below the 200-day MA of 2.63, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 58.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALAFY.

AFYREN Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

FR:ALAFY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:AIFR:AI68NeutralEUR 120.85B32.4913.42%1.61%-1.30%3.05%
FR:CBEFR:CBE63NeutralEUR 1.62B16.54―1.94%0.30%0.78%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
FR:AKEFR:AKE60NeutralEUR 4.40B52.141.28%6.28%-1.70%-42.07%
FR:ALBKKFR:ALBKK55NeutralEUR 70.46M42.673.51%1.56%6.97%-73.50%
FR:ALAFYFR:ALAFY45NeutralEUR 86.64M-11.29-7.49%―-13.62%54.46%
FR:ALCRBFR:ALCRB41NeutralEUR 68.54M-3.41-10.62%―――

* Basic Materials Sector Average

Performance Comparison

-50%-25%0%25%50%FR:ALAFYFR:AIFR:AKEFR:ALCRBFR:ALBKKFR:CBEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALAFY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALAFYAFYREN2.230.000.00%
FR:AIAir Liquide (UK)189.7442.2728.66%
FR:AKEArkema SA (UK)57.3510.4522.29%
FR:ALCRBCarbios SA4.05-5.10-55.68%
FR:ALBKKBaikowski SA19.20-3.33-14.77%
FR:CBERobertet SA Cert.d'Invest. Em.87620.00-101.93-14.12%

AFYREN Corporate Events

AFYREN and MINASOLVE Partner on Bio-Based Fragrance Molecules

Nov 5, 2026

AFYREN is a French greentech company using proprietary fermentation technology and non-food agricultural co-products to make bio-based, low-carbon carboxylic acids. Its solutions serve manufacturers in nutrition, flavors and fragrances, life sciences...

AFYREN’s biosourced propionic acid powers first-of-its-kind skincare launch

Oct 1, 2026

AFYREN is reinforcing its role in sustainable industrial biotechnology by supplying 100% biosourced, COSMOS‑certified propionic acid produced via a low‑carbon, circular fermentation process at its AFYREN NEOXY biorefinery in France. The company focus...

AFYREN and Terrial Renew Multi‑Year Potassium Fertilizer Alliance

Sep 29, 2026

AFYREN and Terrial have renewed their strategic partnership with a new multi‑year fertilizer supply contract worth several tens of millions of euros, centered on AFYREN’s potassium‑rich fertilizer processed by Terrial and marketed in France under the...

AFYREN Takes Full Control of Flagship Plant as Production and Pre-Sold Volumes Surge

Sep 24, 2026

AFYREN has strengthened its industrial profile by acquiring the remaining 49% of its AFYREN NEOXY plant, becoming its sole owner and gaining full control over ramp-up and performance investments. The company successfully executed an optimization prog...

AFYREN scales bio-based acid output and strengthens climate-resilient positioning

Aug 27, 2026

AFYREN has crossed the milestone of 1,000 tonnes of bio-based acids produced at its AFYREN NEOXY biorefinery since ramp-up began in mid-2025, including more than 200 tonnes since operations resumed in July 2026, signalling its transition to full indu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 17, 2026